|1.||Yoshino, Ayako: 1 article (07/2005)|
|2.||Saito, Seiichi: 1 article (07/2005)|
|3.||Yoshimori, Atsushi: 1 article (07/2005)|
|4.||Sugawara, Fumio: 1 article (07/2005)|
|5.||Tanuma, Seiichi: 1 article (07/2005)|
|6.||Sakaguchi, Kengo: 1 article (07/2005)|
|7.||Morohashi, Kengo: 1 article (07/2005)|
|1.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/01/2005 - "Our results show that the anti-tumor activity of NK109 stems from interactions with multiple protein targets."
07/01/2005 - "The synthetic compound NK109 shows anti-tumor effects against a number of human cancer cell lines. "
07/01/2005 - "Identification of a drug target motif: an anti-tumor drug NK109 interacts with a PNxxxxP."
10/01/1996 - "2,3-(Methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthr idinium hydrogensulfate dihydrate, called NK109, is a benzo[c]phenanthridine derivative, which inhibits DNA topoisomerase II activity by stabilizing the DNA-enzyme-drug complex, and shows strong growth-inhibitory effects on several human cancer cells. "
07/01/2005 - "The mechanism of action is thought to involve the inhibition of DNA topoisomerase II. However, NK109 also exhibits potent anti-tumor activities against doxorubicin-, cisplatin- and etoposide-resistant human cell lines. "
|2.||Type II DNA Topoisomerases (Topoisomerase II)
|3.||Etoposide (VP 16)
|5.||DNA (Deoxyribonucleic Acid)